Utilizing Real-World Data to Advance Benign Prostatic Hyperplasia Research

Benign prostatic hyperplasia (BPH) is a prevalent condition affecting millions of aging men worldwide, with significant implications for quality of life and healthcare utilization. 

Real-world data (RWD) is playing an increasingly critical role in helping to understand disease progression, treatment options and outcomes, and clinical trial optimization for BPH. By leveraging structured, semi-structured, and unstructured data from electronic health records (EHRs), RWD provides a more comprehensive view of patient journeys, offering insights that can drive innovation in BPH research and therapeutic development. These innovations are then seen in improved patient outcomes.

The Need for Robust Real-World Data in BPH Research

BPH is a chronic condition with a complex progression that varies across individuals. Traditional clinical trials, while essential, often face challenges in patient recruitment, retention, and generalizability. They can also miss some of the heterogeneity we see in practice. RWD complements these studies by capturing longitudinal patient experiences from routine clinical practice. 

The American Urological Association (AUA) Quality (AQUA)^® Registry includes 13 million de-identified patients from over 2,300 clinicians. Utilizing real-world data from the AQUA Registry, Verana Health applies advanced artificial intelligence techniques, such as machine learning and natural language processing, to derive meaningful insights into benign prostatic hyperplasia (BPH). These insights assist life sciences companies in identifying unmet patient needs, refining patient segmentation, and optimizing clinical trial design, ultimately facilitating the development of more effective treatments.

How Real-World Data Enhances BPH Clinical Research

By combining quality RWD from the AQUA Registry with secure and advanced AI, Verana Health has developed Qdata^® BPH, a research-ready dataset of 1.7 million de-identified patients with a median of 4+ years of follow-up data. The dataset provides:

• Deeper Phenotypic Insights: By analyzing structured EHR fields alongside unstructured clinical notes, researchers can achieve a more nuanced understanding of BPH severity, symptom progression, and treatment response.
• Improved Patient Stratification: RWD enables the identification of clinically relevant patient cohorts, helping to ensure that sponsors and contract research organizations enroll the right populations in clinical trials to accurately evaluate therapeutic efficacy.
• Enhanced External Control Arms: In situations where traditional control groups are difficult to establish, real-world datasets can serve as external control arms, reducing reliance on placebo groups and enhancing study feasibility.
• Longitudinal Outcomes Tracking: By examining patient journeys over time, RWD helps researchers assess long-term treatment effectiveness, adherence patterns, and safety profiles beyond the controlled environment of clinical trials.

Bridging the Gap Between Real-World Data and Clinical Trials

The integration of RWD into clinical research requires a thoughtful approach to data quality, standardization, and regulatory compliance. 

By embracing real-world data in BPH research, we can enhance clinical trial efficiency, unlock new therapeutic opportunities, and ultimately improve patient outcomes. As the field of urology continues to evolve, the synergy between RWD and traditional clinical research will be instrumental in shaping the future of BPH treatment strategies and care.